1. Home
  2. JQC vs REPL Comparison

JQC vs REPL Comparison

Compare JQC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

N/A

Current Price

$4.76

Market Cap

753.9M

Sector

Finance

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$8.52

Market Cap

692.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JQC
REPL
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
692.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
JQC
REPL
Price
$4.76
$8.52
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$11.13
AVG Volume (30 Days)
823.8K
1.1M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.60
$2.68
52 Week High
$5.58
$13.24

Technical Indicators

Market Signals
Indicator
JQC
REPL
Relative Strength Index (RSI) 26.33 59.10
Support Level N/A $8.24
Resistance Level $5.16 $8.82
Average True Range (ATR) 0.05 0.57
MACD -0.02 0.04
Stochastic Oscillator 8.62 87.19

Price Performance

Historical Comparison
JQC
REPL

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: